Skip to content

Weekly brief · October 26, 2026

The Med Spa Brief

This week: beauty giants chase the 'Ozempic face' market, a crackdown on experimental GLP-1s, and hard lessons from masseter Botox gone wrong.

Dr. Braun from Vancouver, Canada · CC BY-SA 2.0
Treatments & Tech

Beauty Giants Race to Treat the 'Ozempic Face'

Reuters reports that major cosmetics and skincare companies are building product lines aimed at the facial volume loss and sagging that often accompanies rapid GLP-1 weight loss. The surge in obesity-drug use is opening a lucrative new category spanning fillers, skin tightening, and topicals.

Why it matters: GLP-1 patients are already walking into med spas with volume loss — this is a concrete revenue lane if you package treatments for it.

US · Oct 23Reuters

More this week

The Med Spa Brief is curated and written automatically each week. Summaries are original and link to their sources — we don't republish others' articles. Images are used under their Wikimedia Commons licenses, credited where shown.